Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELIEF-CSU1: ARS-1 in Frequent Urticaria Flares
NCT05496465Phase 2
Key facts
- Status
- Completed
- Start
- Jul 2022
- Primary completion
- Feb 2024
- Countries
- 1
- Sponsor
- ARS Pharmaceuticals
- Modality
- Small Molecules, Device-based Delivery
- Drugs
- eurneffy
- Conditions
- urticaria
01
Overview
Phase 2, randomised trial of eurneffy in urticaria (2 arms), sponsored by ARS Pharmaceuticals. Primary endpoint: Urticaria Activity Score at 120 minutes. Started Jul 2022; status: completed.
02
Design
2 arms- Study design
- Randomized
Sequence 1
1 mg ARS-1 IN -> placebo -> 2 mg ARS-1 IN
Sequence 2
2 mg ARS-1 IN -> placebo -> 1 mg ARS-1 IN
03
Who it enrols
Adults aged 18-65 with clinically diagnosed urticaria experiencing frequent acute flares despite chronic treatment, with BMI 18-34 kg/m2, excluding those with cardiovascular disease, hypertension, or taking beta blockers.
04
Endpoints
Primary
Urticaria Activity Score
Beyond the preview
Go deeper on NCT05496465.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496465.